Adverse events during anti-TNFα therapies in IBD (Excluding Infections and Malignancies): When to stop, continue, or switch therapies

Priya Sehgal, Jean Frederic Colombel, Neeraj Narula

Research output: Contribution to journalReview articlepeer-review

6 Scopus citations

Abstract

There are several adverse events that can occur in the setting of tumor necrosis factor-α inhibitor treatment for inflammatory bowel disease. The most common side effects include infection and malignancy. There are however several less frequent adverse events that can be classified as dermatologic, neurologic, cardiac, and hepatic. The aim of this review was to assist clinicians to recognize and manage these infrequent adverse events that occur during use of tumor necrosis factor-α antagonists.

Original languageEnglish
Pages (from-to)1239-1245
Number of pages7
JournalInflammatory Bowel Diseases
Volume22
Issue number5
DOIs
StatePublished - 1 May 2016

Keywords

  • Crohn's disease
  • IBD
  • TNFα inhibitors
  • adverse events
  • anti-TNF
  • infliximab
  • ulcerative colitis

Fingerprint

Dive into the research topics of 'Adverse events during anti-TNFα therapies in IBD (Excluding Infections and Malignancies): When to stop, continue, or switch therapies'. Together they form a unique fingerprint.

Cite this